Peter Rahmer Sells 748 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 748 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $18.61, for a total transaction of $13,920.28. Following the completion of the transaction, the insider directly owned 228,165 shares in the company, valued at approximately $4,246,150.65. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, June 30th, Peter Rahmer sold 50,000 shares of Relay Therapeutics stock. The shares were sold at an average price of $19.09, for a total transaction of $954,500.00.

Relay Therapeutics Stock Performance

Shares of Relay Therapeutics stock opened at $18.83 on Friday. The firm has a fifty day moving average of $17.16 and a two-hundred day moving average of $13.07. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of -11.99 and a beta of 1.67. Relay Therapeutics, Inc. has a 52 week low of $3.03 and a 52 week high of $20.79.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.58 million. As a group, research analysts forecast that Relay Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RLAY. Commodore Capital LP bought a new stake in shares of Relay Therapeutics in the second quarter worth about $46,191,000. Perceptive Advisors LLC raised its position in shares of Relay Therapeutics by 412.3% during the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock worth $97,024,000 after purchasing an additional 7,847,896 shares during the period. Spruce Street Capital LP bought a new position in shares of Relay Therapeutics during the 4th quarter valued at about $25,246,000. EcoR1 Capital LLC acquired a new position in shares of Relay Therapeutics in the 1st quarter valued at approximately $18,952,000. Finally, TCG Crossover Management LLC acquired a new position in shares of Relay Therapeutics in the 3rd quarter valued at approximately $9,450,000. 96.98% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Potential earnings catalyst: Zacks expects Relay Therapeutics could exceed consensus expectations in its upcoming quarterly report, which may support near-term investor sentiment. This is only an earnings preview, not a reported result. Relay Therapeutics Expected to Beat Earnings Estimates
• Positive Sentiment: Breast cancer program draws renewed interest: Coverage says Relay’s breast cancer program has revitalized the investment story, potentially expanding the company’s opportunity in oncology. Relay Therapeutics Revitalized by Breast Cancer Program
• Positive Sentiment: Institutional ownership and analyst support remain strong: Several funds increased their positions during the first quarter, and recent analyst targets generally imply additional upside. MarketBeat reports a “Moderate Buy” consensus rating with an average target of $24.92.
• Neutral Sentiment: Second-quarter results are scheduled for August 6: Relay will report financial results and corporate updates after the market close. Investors will likely focus on pipeline progress, cash resources and development plans. Relay Therapeutics Second-Quarter Results Announcement
• Neutral Sentiment: Insider selling was administrative: CFO Thomas Catinazzo and insiders Donald Bergstrom and Peter Rahmer sold a combined 4,444 shares at $18.61 to cover tax withholding on vested equity awards. Each retained substantial holdings, limiting the bearish significance of the transactions. Relay Therapeutics Insider Transactions
• Negative Sentiment: Competition and clinical risk remain material: Relay is still a clinical-stage biotechnology company, and its valuation depends heavily on successful trials and eventual commercialization. Intense competition in breast cancer could limit the program’s upside.

Analyst Ratings Changes

A number of brokerages have issued reports on RLAY. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Monday, July 6th. Wall Street Zen raised Relay Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Raymond James Financial reiterated a “strong-buy” rating on shares of Relay Therapeutics in a research report on Tuesday, May 19th. HC Wainwright lifted their price objective on shares of Relay Therapeutics from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Finally, Citigroup restated an “outperform” rating on shares of Relay Therapeutics in a report on Wednesday, May 20th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.92.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.